In the last trading session, the stock price of Delcath Systems, Inc. (NASDAQ:DCTH) jumped more than 17% to close the day at $0.122. After the recent gains, the market cap of firm now stands at $60.63 million.
More recently, the company congratulated the team at the renowned Medical University of Hannover Hospital on their exception performance of the hospital’s 100th PHP® procedure with CHEMOSAT®. The team, headed by Professor Dr. Frank Wacker and Professor Dr. Michael Manns, celebrated the institution’s feat at a ceremony on August 18, 2017.
PHP with HDS/Melphalan was advanced by Delcath Systems as an intended, whole organ treatment for the liver. The offering is commercially offered in Europe under the name “CHEMOSAT”, and is being assessed as an investigational therapy in the United States. Delcath is presently registering subjects in the FOCUS study, an international Phase 3 clinical study that is investigating PHP with HDS/Melphalan as a treatment for subjects with ocular melanoma and has metastasized to the liver. The company intends to commence enrollment in a Registration study for intrahepatic cholangiocarcinoma in 2017.
PHP is a minimally invasive process that isolates the liver from the circulatory system. This is done so as to infuse a high dose of chemotherapy directly into the liver with the prospective to cure both non-visualized and visualized metastases. Later blood from the liver is filtered to eliminate the chemotherapeutic agent, hence reducing systemic exposure and possibly the related side effects.
As it is known, the Medical University of Hannover was established in 1965, and is a renowned university medical center research based in Germany. It boasts an exceptional reputation in interdisciplinary collaboration within extramural scientific institutions as well as the MHH, and is the German medical university recording the top volume of grant funding.